WG
NKTR icon

Winton Group’s Nektar Therapeutics NKTR Stock Holding History

Winton Group’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.81M Buy
25,900
+8,990
+53% +$658K 0.06% 313
2026
Q1 		$1.22M Buy
16,910
+9,145
+118% +$521K 0.04% 477
2025
Q4 		$328K Buy
+7,765
New +$435K 0.01% 726
2020
Q4 		– Sell
-3,046
Closed -$758K – 1452
2020
Q3 		$758K Sell
3,046
-3,770
-55% -$1.19M 0.02% 937
2020
Q2 		$2.37M Sell
6,816
-701
-9% -$219K 0.06% 569
2020
Q1 		$2.01M Sell
7,517
-9,367
-55% -$2.9M 0.05% 574
2019
Q4 		$5.47M Buy
16,884
+13,561
+408% +$3.93M 0.08% 433
2019
Q3 		$908K Buy
3,323
+2,837
+584% +$1.04M 0.01% 878
2019
Q2 		$259K Buy
486
+36
+8% +$18.1K 0.01% 945
2019
Q1 		$227K Sell
450
-230
-34% -$136K ﹤0.01% 912
2018
Q4 		$335K Buy
680
+196
+40% +$118K 0.01% 622
2018
Q3 		$443K Sell
484
-28
-5% -$23.9K 0.01% 677
2018
Q2 		$375K Buy
512
+149
+41% +$172K 0.01% 738
2018
Q1 		$579K Buy
+363
New +$468K 0.02% 704

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Winton Group's NKTR Position: Q2 2026 in Review

Winton Group increased its Nektar Therapeutics (NKTR) stake by 53% in Q2 2026, buying an estimated $658K and bringing the position to 25,900 shares worth $1.81M. The position accounts for 0.06% of the portfolio, ranked #313.

Winton Group first reported a position in NKTR in Q1 2018 and has held it in 14 quarters since. The position peaked at $5.47M in Q4 2019. 239 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • Winton Group held 25,900 shares of Nektar Therapeutics worth $1.81M as of Q2 2026.
  • Winton Group bought 8,990 Nektar Therapeutics shares in Q2 2026, an estimated $658K.
  • Nektar Therapeutics made up 0.06% of Winton Group's portfolio in Q2 2026, its #313 holding.
  • Winton Group first reported a position in Nektar Therapeutics in Q1 2018 and has held it in 14 quarters since.
  • Winton Group's Nektar Therapeutics position peaked at $5.47M in Q4 2019.
  • 239 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on Winton Group's 13F filing for Q2 2026, filed 7 Aug 2026.